High-Purity Voacangine for Ibogaine-Based Drug Development
Reliable, scalable supply of voacangine for R&D and clinical-stage programs — with ongoing development of ibogaine production.
About us
Hylaea is a Brazilian biotech company supplying voacangine as a strategic semisynthetic precursor for ibogaine and next-generation derivatives.
In parallel, we are developing the production of ibogaine hydrochloride, advancing toward a fully integrated supply of ibogaine-based compounds.
differential
Our Principles of Excellence
01
Amazon Certification
Our products support Amazon preservation through sustainable practices, honoring the work of our team and local communities while driving innovation and environmental responsibility.
02
Sustainable Raw Materials
We combine sustainable practices and advanced technology to deliver high-quality, scalable compounds while preserving the Amazon’s ecological balance.
03
Unmatched Purity
We produce voacangine with >99% purity, combining advanced technology and sustainability to deliver reliable, high-performance products for the global market.
04
Large-Scale Production & Service
Hylaea operates a scalable production model with GMP-compliant voacangine manufacturing, ensuring consistent supply, high-capacity output, and continuous innovation for the global pharmaceutical industry.
05
Patent Registration & Technology Transfer
A patent application is underway, reinforcing Hylaea’s commitment to innovation, IP protection, and exclusive, high-quality production processes.
Learn a little more about our history
FAQ
Your questions answered